 |
University of Kansas School of Medicine | |
| City: Kansas City | State: KS | |
|
Links:
Commentary:Vendor_relations_policy__Revision_date_Nov._1__2011.pdf Sales_and_Service_Representatives.pdf Pharmaceutical_Sample_Medications.pdf KU_Hospital_Formulary_Policy.pdf Pharmacuetical_Industry__Presentation.pdf Summary: University of Kansas School of Medicine has enacted exemplary policies in areas concerning gifts, consulting relationships, and disclosure. There is public disclosure via a website. All other areas are strong and could benefit from some minor improvements. Policies on speaking relationships could be strengthened by clearly prohibiting long-term speaking relationships such as speakers bureaus. Pharmaceutical samples are restricted, but could be limited further placing restrictions on who receives them, and not allowing them to be used in outpatient clinics. The Purchasing & Formularies policy score actually decreased this year, it appears that recusal was required if a COI was present, but that no longer seems to be the case. Demographics: Students spend the vast majority of their training at University of Kansas Hospital. Submitted policies apply to personnel and students regardless of location Updates: This institution did not submit any new or additional policies for the 2012-13 AMSA PharmFree Scorecard. This institution's evaluation was last updated: 02/29/2012 |
||
| Gifts & Meals |  |
The policy explicitly prohibits gifts, including meals, regardless of value. |
| Consulting relationships | |
The policy requires annual review of consulting relationships from Department chairmen in addition to, "an explicit contract with specific deliverables, and the deliverables must be restricted to scientific issues, not marketing efforts, and compensation must be commensurate with the consulting task being performed." |
| Industry-funded speaking relationships |  |
"Speaker's bureaus" are not prohibited in the policy and prevention of long term speaking relationships is not established in the policy. Speaking relationships are limited to guidelines, including none industry control of speaker's content. |
| Disclosure | |
The policy mandates public disclosure via a website of inancial conflicts of interest between clinicians engaged in clinical treatment or clinical research. |
| Pharmaceutical samples | |
The policy prohibits samples in inpatient hospital areas and mandates authorized areas for samples, including the pharmacy department. Representatives must have an appointment when delivering samples to authorized areas. |
| Purchasing & Formularies | |
Disclosure to the purchasing unit and Conflict of Interest Committee is required prior to decision making and the COI Committee determines individual recusal from the purchasing decision. |
| Industry Sales Representatives | |
The policy requires a pre-scheduled appointment for industry sales representatives and vendor registration at every visit. |
| On-campus Education | |
The policy improved this year by requiring all funds be made to a central account "not designated for use by specific individuals" and by clearly stating the independence of funds from industry control. |
| Attendance at Industry-Sponsored Lectures & Meetings Off-Campus | |
Manufacturers interested in having faculty, house-staff or students attend meetings should provide grants to a designated fund at the School of Medicine. This body will then disburse funds to faculty and training program directors. Neither faculty nor trainees will be directly dependent on individual generosity for their educational opportunities. |
| Industry Support for Scholarships & Funds for Trainees | |
The policy establishes oversight and approval, via the EVC, of unrestricted grants which are compliant with the ACCME standards. |
| Medical school curriculum | |
The institution's training materials promote an sufficient understanding of the medical device/pharmaceutical industry and interaction with physicians. |
| Do the policies specify an oversight mechanism? |  |
This policy specifies an oversight mechanism. |
| Are there explicit sanctions for noncompliance? | |
Sanctions referenced. |
 | |
 | Model policy |
 | Good progress toward model policy |
 | No policy, or policy unlikely to have a substantial effect on behavior |
 | Did not report |
 | Policy not relevant to this institution (e.g., does not make purchasing decisions) |
